SEPAR Guidelines for Lung Cancer Staging

Cos, Julio Sánchez de; Hernández, Jesús Hernández; López, Marcelo F.; Sánchez, Susana Padrones; Gratacós, Antoni Rosell; Porta, Ramón Rami

doi:10.1016/j.arbr.2011.06.007

Cited by 35 publications

(8 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, the risk for LC increases in patients with underlying respiratory conditions such as chronic obstructive pulmonary disease (COPD), which also constitutes a major cause of morbidity and mortality in developed countries (1)(2)(3)(4)(5)(6)(7). Interestingly, 59 patients with LC who also had COPD (57 males; 2 females).…”

mentioning

confidence: 99%

Redox Imbalance in Lung Cancer of Patients with Underlying Chronic Respiratory Conditions

Mateu-Jiménez

Sánchez-Font

Rodríguez-Fuster

et al. 2016

Mol Med

View full text Add to dashboard Cite

Chronic respiratory diseases such as obstructive pulmonary disease (COPD) and oxidative stress may underlie lung cancer (LC). We hypothesized that the profile of oxidative and antioxidant events may differ in lung tumors and blood compartments of patients with non-small cell LC (NSCLC) with and without COPD. Redox markers (immunoblotting, ELISA, chemiluminescence, 2D electrophoresis and proteomics) were analyzed in blood samples of 17 control subjects and 80 LC patients (59 LC-COPD and 21 LC) and lung specimens (tumor and nontumor) from those undergoing thoracotomy (35 patients: 23 LC-COPD and 12 LC). As smoking history was more prevalent in LC-COPD patients, these were further analyzed post hoc as heavy and moderate smokers (cutoff, 60 pack-years). Malondialdehyde (MDA)-protein adducts and SOD1 levels were higher in tumor and nontumor samples of LC-COPD than in LC. In tumors compared with nontumors, SOD2 protein content was greater, whereas catalase levels were decreased in both LC and LC-COPD patients. Blood superoxide anion levels, protein carbonylation and nitration were greater in LC and LC-COPD patients than in the controls, and in the latter patients compared with the former. Systemic superoxide anion, protein carbonyls and nitrotyrosine above specific cutoff values best identified underlying COPD among all patients. Smoking did not influence the study results. A differential expression profile of oxidative stress markers exists in blood and, to a lesser extent, in the tumors of LC-COPD patients. These findings suggest that systemic oxidative stress and lung antioxidants (potential biomarkers) may predispose patients with chronic respiratory diseases to a higher risk for LC.

show abstract

mentioning

confidence: 99%

Redox Imbalance in Lung Cancer of Patients with Underlying Chronic Respiratory Conditions

Mateu-Jiménez

Sánchez-Font

Rodríguez-Fuster

et al. 2016

Mol Med

View full text Add to dashboard Cite

show abstract

“…In line with this, it has also been well established that patients with underlying respiratory conditions such as chronic obstructive pulmonary disease (COPD), which also represents a major cause of morbidity and mortality in developed countries, exhibit a significantly greater risk of LC (3,(10)(11)(12)(13)(14)(15)(16)(17). Importantly, in patients with moderate-to-severe COPD, the prevalence of LC can go up as high as five-fold that of smokers without the disease (18)(19)(20)(21)(22)(23)(24).…”

Section: Introductionmentioning

confidence: 79%

Relationships between chronic obstructive pulmonary disease and lung cancer: biological insights

Barreiro¹,

Bustamante

Curull³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Lung cancer (LC) has become one of the leading causes of preventable death in the last few decades. Cigarette smoking (CS) stays as the main etiologic factor of LC despite that many other causes such as occupational exposures, air pollution, asbestos, or radiation have also been implicated. Patients with chronic obstructive pulmonary disease (COPD), which also represents a major cause of morbidity and mortality in developed countries, exhibit a significantly greater risk of LC. The study of the underlying biological mechanisms that may predispose patients with chronic respiratory diseases to a higher incidence of LC has also gained much attention in the last few years. The present review has been divided into three major sections in which different aspects have been addressed: (I) relevant etiologic agents of LC; (II) studies confirming the hypothesis that COPD patients are exposed to a greater risk of developing LC; and (III) evidence on the most relevant underlying biological mechanisms that support the links between COPD and LC. Several carcinogenic agents have been described in the last decades but CS remains to be the leading etiologic agent in most geographical regions in which the incidence of LC is very high. Growing evidence has put the line forward the implications of COPD and especially of emphysema in LC development. Hence, COPD represents a major risk factor of LC in patients. Different avenues of research have demonstrated the presence of relevant biological mechanisms that may predispose COPD patients to develop LC. Importantly, the so far identified biological mechanisms offer targets for the design of specific therapeutic strategies that will further the current treatment options for patients with LC. Prospective screening studies, in which patients with COPD should be followed up for several years will help identify biomarkers that may predict the risk of LC among these patients.

show abstract

“…19 PET-CT contributes to cancer staging 2,3 by evaluating mediastinal and systemic metastasis, and is recommended in many LC management guidelines. 17,18,20 In these recommendations, PET-CT is used in two ways: as a tool for characterizing the SPN and as a staging technique in SPNs with high PM.…”

Section: Positron Emission Tomographymentioning

confidence: 99%

“…20 Another aim is to avoid submitting patients with granulomas, hamartomas and other benign lesions to costly and risky treatments. There is no singly accepted procedure.…”

Section: Sequential Evaluation Of the Solitary Pulmonary Nodulementioning

confidence: 99%